Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis.
Awazu Y, Mizutani A, Nagase Y, Iwata H, Oguro Y, Miki H, Imamura S, Hori A. Awazu Y, et al. Cancer Sci. 2012 May;103(5):939-44. doi: 10.1111/j.1349-7006.2012.02238.x. Epub 2012 Mar 15. Cancer Sci. 2012. PMID: 22320850 Free PMC article.
Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
Awazu Y, Mizutani A, Nagase Y, Tsuchiya S, Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto N, Iwata H, Miki H, Imamura S, Hori A. Awazu Y, et al. Cancer Sci. 2013 Apr;104(4):486-94. doi: 10.1111/cas.12101. Epub 2013 Feb 18. Cancer Sci. 2013. PMID: 23305239 Free PMC article.
Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.
Miyamoto N, Sakai N, Hirayama T, Miwa K, Oguro Y, Oki H, Okada K, Takagi T, Iwata H, Awazu Y, Yamasaki S, Takeuchi T, Miki H, Hori A, Imamura S. Miyamoto N, et al. Among authors: awazu y. Bioorg Med Chem. 2013 Apr 15;21(8):2333-2345. doi: 10.1016/j.bmc.2013.01.074. Epub 2013 Feb 13. Bioorg Med Chem. 2013. PMID: 23498918
Structure-based discovery of cellular-active allosteric inhibitors of FAK.
Tomita N, Hayashi Y, Suzuki S, Oomori Y, Aramaki Y, Matsushita Y, Iwatani M, Iwata H, Okabe A, Awazu Y, Isono O, Skene RJ, Hosfield DJ, Miki H, Kawamoto T, Hori A, Baba A. Tomita N, et al. Among authors: awazu y. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85. doi: 10.1016/j.bmcl.2013.01.047. Epub 2013 Jan 26. Bioorg Med Chem Lett. 2013. PMID: 23414845
Predicting recurrence in intermediate‑ and high‑risk stage IB‑IIB cervical cancer treated with adjuvant cisplatin and paclitaxel chemotherapy post‑radical hysterectomy: The role of TBX2 expression.
Noda T, Fukuda T, Uchikura E, Awazu Y, Wada T, Tasaka R, Yamauchi M, Yasui T, Sumi T. Noda T, et al. Among authors: awazu y. Oncol Lett. 2024 Jun 28;28(3):414. doi: 10.3892/ol.2024.14547. eCollection 2024 Sep. Oncol Lett. 2024. PMID: 38988440 Free PMC article.
29 results